Other languages Luye Pharma Group Ltd.

Equities

2186

BMG570071099

Delayed Hong Kong S.E. Other stock markets 06:20:36 03/05/2024 BST			5-day change	1st Jan Change
3.01 ^HKD	-0.33%		+13.96%	-19.03%

03-27	Luye Pharma Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-07	Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Luye Pharma Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27
Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao	03-07
Luye Enrolls First Patient into Phase III Trial of Anti-Cancer Drug	03-04
Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610	03-04
Luye Pharma's Schizophrenia Injectable Surpasses Patent Challenges in US; Shares Fall 3%	02-02
Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension in the United States	02-01
Luye Pharma Says Two Medications Added to China's National Reimbursement Drug List	12-13
Luye Pharma's Small Cell Lung Cancer Treatment Secures Hong Kong Marketing Approval	12-13
Pharma Mar Partner Wins Marketing Approval for Lung Cancer Drug in Hong Kong	12-12
Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong Kong	12-12
Luye Pharma Group Ltd. Announces Board Changes	12-06
Chinese Regulator Green Lights Luye Pharma’s Small Cell Lung Cancer Drug	12-04
Pharma Mar Partner Wins Approval for Lung Cancer Drug in Macao	12-04
China Gives Marketing Green Light to Luya Pharma's Patch Treatment for Alzheimer's Disease	11-01
Luye Pharma Group Ltd. Announces Rivastigmine Twice Weekly Transdermal Patch Approval for Marketing in China	31/10/23
Luye Pharma Files New Drug Application in US for Schizophrenia Medication	09/10/23
Luye Pharma Group Ltd. Submits New Drug Application to the U.S. Food and Drug Administration Through the 505(B)(2) Pathway for Paliperidone Palmitate Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder	09/10/23
China Approves Luye Pharma's Breast Cancer Injectable	08/09/23
Luye Pharma Group Ltd. Announces the Innovative Formulation, Goserelin Microspheres for Injection Approved by the National Medical Products Administratio	07/09/23
Luye Pharma Group Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	29/08/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Luye Pharma Group Ltd.

Equities

2186

BMG570071099

Other languages

Filters